NCT06962215 The Impact of Paramedic Training in Simulation on the Experience of Patients Treated for Malignant Brain Tumors in Neurosurgery (IPSIMANON)
| NCT ID | NCT06962215 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Brest |
| Condition | Brain Tumor Adult |
| Study Type | INTERVENTIONAL |
| Enrollment | 250 participants |
| Start Date | 2025-05-15 |
| Primary Completion | 2027-05 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 250 participants in total. It began in 2025-05-15 with a primary completion date of 2027-05.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to demonstrate that simulation training for paramedical staff in neurosurgery departments, in announcing and accompanying patients with a brain tumor, improves patient satisfaction when a (potentially malignant) brain tumor is discovered, compared with usual care. The main question it aims to answer is: \- Are patients more satisfied (as measured by scores on the EORCT IN-PATSAT32 questionnaire) with their neurosurgical hospitalization following the discovery of a brain tumor in centers where paramedics have been trained by simulation? Researchers will compare the results of the EORTC IN-PATSAT32 questionnaire to determine whether paramedic training improves patient satisfaction between simulation-trained and untrained centers. Participants will be asked to complete the EORT IN-PATSAT32 questionnaire at the end of their hospital stay.
Eligibility Criteria
Inclusion Criteria: * Patient over 18 years of age * Patient covered by a social security scheme * Patient signed informed consent form * Patient found to have a brain tumor (potentially malignant, primary or secondary if this is the mode of entry into the disease) * Hospitalization in the Neurosurgery Department at the time of tumor discovery, before the histological diagnosis is announced. Exclusion Criteria: * Patients with a personal history of cancer * Patient without family AND unable to receive information
Contact & Investigator
Valérie QUEMENEUR
STUDY DIRECTOR
CHU Brest
Frequently Asked Questions
Who can join the NCT06962215 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Brain Tumor Adult. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06962215 currently recruiting?
Yes, NCT06962215 is actively recruiting participants. Contact the research team at doriane.gautier@chu-brest.fr for enrollment information.
Where is the NCT06962215 trial being conducted?
This trial is being conducted at Brest, France, Amiens, France, Angers, France, Bordeaux, France and 7 additional locations.
Who is sponsoring the NCT06962215 clinical trial?
NCT06962215 is sponsored by University Hospital, Brest. The principal investigator is Valérie QUEMENEUR at CHU Brest. The trial plans to enroll 250 participants.